Pacira BioSciences' Convertible Debt fell 4155.61% to $280.3 million in Q2 2025 from the same period last year, while for Jun 2025 it was $280.3 million, marking a year-over-year decrease of 4155.61%. This contributed to the annual value of $279.3 million for FY2024, which is 2992.02% down from last year.
As of Q2 2025, Pacira BioSciences' Convertible Debt stood at $280.3 million, which was down 4155.61% from $279.8 million recorded in Q1 2025.
Over the past 5 years, Pacira BioSciences' Convertible Debt peaked at $479.5 million during Q2 2024, and registered a low of $278.9 million during Q3 2024.
Over the past 5 years, Pacira BioSciences' median Convertible Debt value was $397.7 million (recorded in 2023), while the average stood at $362.0 million.
As far as peak fluctuations go, Pacira BioSciences' Convertible Debt surged by 2696.71% in 2022, and later plummeted by 4155.61% in 2025.
Pacira BioSciences' Convertible Debt (Quarter) stood at $339.3 million in 2021, then rose by 19.31% to $404.8 million in 2022, then decreased by 1.53% to $398.6 million in 2023, then dropped by 29.92% to $279.3 million in 2024, then grew by 0.33% to $280.3 million in 2025.
Its last three reported values are $280.3 million in Q2 2025, $279.8 million for Q1 2025, and $279.3 million during Q4 2024.

Peer Comparison

Historic Data

Download Data 🔒

Date	Value